The Debt to Equity Ratio is a company’s total liabilities divided by its shareholder equity. It's the degree to which a company is financing its operations through debt v/s wholly owned funds

Lower than Industry Debt to Equity Ratio

Current ratio measures a company’s ability to pay short-term obligations. Higher is better

Lower than Industry Current Ratio

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Lower than Industry Revenue Growth

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Decreasing Market Share

Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Lower than Industry Net Income

The EBITDA margin is the percent of revenue that the company retains after incurring all the direct and operational costs of the business

Lower than Industry EBITDA Margin

The net profit margin is net income or profit generated as a percentage of revenue and illustrates how much of each rupee in revenue translates to profit

Lower than Industry Net Profit Margin

Y-o-y growth in the total revenue represents increased potential for the company to increase their market share.Total revenue for the current quarter is compared with the same quarter of previous year to reduce the effects of seasonality

Increasing Total Revenue

Y-o-y growth in the net income represents increased profitability of the company.Net profit for the current quarter is compared with the same quarter of previous year to reduce the effects of seasonality

Increasing Net Profit

Increasing EBITDA margin indicates increased profit efficiency without taking into account financial, accounting or tax implications

Constant EBITDA Margin

Increasing Net profit margins indicates the increasing profit to the shareholders with each unit of revenue

Constant Net Profit Margin

Y-o-y growth in the EBITDA represents how efficiently the company manages its expenses.EBITDA for the current quarter is compared with the same quarter of previous year to reduce the effects of seasonality

Increasing EBIDTA

Fortis Healthcare Limited has submitted to the Exchange a copy of the presentation on financial Statements for the quarter ended on June 30, 2016 .

Investor Presentation

Fortis Healthcare Limited has informed the Exchange regarding Investor Presentation

Fortis Healthcare Limited has informed the Exchange regarding Investor PresentationPlease find enclosed the Investorsￂﾒ Presentation on financial Statements for the Quarter ended on September 30, 2017 and December 31, 2017 pursuant to Regulation 30, Schedule III, Part A (15) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.You are requested to take the same on your record

Fortis Healthcare Limited has informed the Exchange regarding Investor PresentationThis is with reference to our letter ref. no. FHL/SEC/STEX/RR/2018-19 dated June 27, 2018 captioned Outcome of the Adjourned Board Meeting dated June 26, 2018, please find attached Investor Presentation for your reference and records.You are kindly requested to take the same on record

Fortis Healthcare Limited has informed the Exchange regarding Investor PresentationPursuant to the provisions of Regulation 30 of SEBI (Listing Obligations and Disclosures Requirement) Regulation, 2015, please find enclosed Investorsￂﾒ Presentation on financial results for quarter and period ended December 31, 2018. This is for your information and records please.

Fortis Healthcare Limited has informed the Exchange regarding  Board meeting held on August 06, 2019.Pursuant to the provisions of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, this is to inform you that the Board of Directors of the Company at its meeting held today i.e. August 6, 2019, inter-alia, considered and approved: -1. Standalone and consolidated un-audited financial results of the Company for the quarter ended on June 30, 2019 along with limited review report thereon; 2. Convening of 23rd Annual General Meeting of the Company on Thursday, September 26, 2019 at National Institute of Pharmaceutical Education and Research, Sector 67, SAS Nagar Mohali- Punjab, 160062.Please find enclosed standalone and consolidated un-audited financial results along with limited review report given by the Statutory Auditor of the Company for quarter ended on June 30, 2019 and a copy of the press release and investor presentation being issued in this regard.The Board Meeting commenced at 0930 Hours and concluded at 1715 Hours.

Fortis Healthcare Limited has informed the Exchange regarding Investor Presentation  for the financial results of the Company for the quarter and period ended on December 31, 2019.

Fortis Healthcare Limited has informed the Exchange about Investor Presentation

Pursuant to the provisions of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, this is to inform you that the Board of Directors of the Company at its meeting held today i.e. August 13, 2021, inter-alia, considered and approved standalone and consolidated un-audited financial results of the Company for the period ended on June 30, 2021 along with limited review report thereon.ￂﾠAccordingly, please find enclosed standalone and consolidated un-audited financial results along with limited review report given by the Statutory Auditor of the Company for period ended on June 30, 2021. Further, a copy of the press release and investor presentation being issued in this regard is also enclosed.ￂﾠThe meeting commenced at 1100 Hours IST and concluded at 1740 Hours IST.ￂﾠThis is for your information and records please.

Pursuant to the provisions of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, this is to inform you that the Board of Directors of the Company at its meeting held today i.e. November 12, 2021, inter-alia, considered and approved standalone and consolidated un-audited financial results of the Company for the period ended on September 30, 2021.Accordingly, please find enclosed standalone and consolidated un-audited financial results along with limited review report given by the Statutory Auditor of the Company for period ended on September 30, 2021. Further, a copy of the press release and investor presentation being issued in this regard is also enclosed.The meeting commenced at 1200 Hours IST and concluded at 1855 Hours IST.This is for your information and records please.

Pursuant to the provisions of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, this is to inform you that the Board of Directors of the Company at its meeting held today i.e. February 11, 2022, inter-alia, considered and approved standalone and consolidated un-audited financial results of the Company for the period ended on December 31, 2021.Accordingly, please find enclosed standalone and consolidated un-audited financial results along with limited review report given by the Statutory Auditor of the Company for period ended on December 31, 2021. Further, a copy of the press release and investor presentation being issued in this regard is also enclosed.The meeting commenced at 1200 Hours IST and concluded at 1910 Hours IST.This is for your information and records please.

Pursuant to the provisions of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, this is to inform you that the Board of Directors of the Company at its meeting held today i.e. May 25, 2022, inter-alia, considered and approved the following:(i)	Audited Standalone and Consolidated Financial results of the Company for the quarter and financial year ended March 31, 2022. M/s B S R and Co. LLP, the Statutory Auditors of the Company have issued an Audit Report with unmodified opinion.Further, a copy of the press release and investor presentation being issued in this regard is also enclosed.(ii)	Re-appointment of Mr. Ravi Rajagopal, Ms. Suvalaxmi Chakraborty and Mr. Indrajit Banerjee as Independent Directors of the Company, subject to approval of the shareholders, for the second term of upto 5 years.

Pursuant to the provisions of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, this is to inform you that the Board of Directors of the Company at its meeting held today i.e. August 5, 2022, inter-alia, considered and approved the following:(i)	Standalone and Consolidated un-audited financial results of the Company for the quarter ended on June 30, 2022. Accordingly, please find enclosed standalone and consolidated un-audited financial results along with limited review report given by the Statutory Auditor of the Company for the quarter ended on June 30, 2022. Further, a copy of the press release and investor presentation being issued in this regard is also enclosed.(ii)	Amalgamation of Fortis Asia Healthcare Pte Limited (￢ﾀﾘFAHPL￢ﾀﾙ) and Fortis Healthcare International Pte Limited (￢ﾀﾘFHIPL￢ﾀﾙ), step-down wholly-owned subsidiaries of the Company.

Pursuant to the provisions of_ Regulation 30 of SEBI (Listing Obligations and Disclosure  Requirements) Regulation, 2015, this is to inform you that the Board of Directors of the Company at its meeting held today i.e. November 11, 2022, inter-alia, considered and approved standalone and consolidated un-audited financial results of the Company for the qua1ter and period ended on September 30, 2022.Accordingly, please find enclosed standalone and consolidated un-audited financial results along with limited review report given by the Statutory Auditor of the Company for the qua1ter and period ended on September 30, 2022. Fu1ther, a copy of the press release and investor presentation being issued in this regard is also enclosed. ￂﾷThe meeting commenced at 0900 Hours 1ST and concluded at 1800 Hours 1ST.

Pursuant to the provisions of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, this is to inform you that the Board of Directors of the Company at its meeting held today i.e. February 10, 2023, inter-alia, considered and approved the Standalone and Consolidated un-audited financial results of the Company for the quarter and period ended on December 31, 2022. Accordingly, please find enclosed standalone and consolidated un-audited financial results along with limited review report given by the Statutory Auditor of the Company for the quarter and period ended on December 31, 2022. Further, a copy of the press release and investor presentation being issued in this regard is also enclosed.

Price return has been average, nothing exciting

Performance

Seems to be overvalued vs the market average

Valuation

Lagging behind the market in financials growth

Growth

Showing good signs of profitability & efficiency

Profitability

The stock is overpriced but is not in the overbought zone

Current price is more than the intrinsic value

Fundamentals

Good time to consider, stock is not in the overbought zone

Technicals

Entry point

Promoter pledged holding

Unsolicited messages

Default probability

Red flags

Fortis Healthcare Limited is an integrated healthcare delivery service provider. The Company is engaged in establishing, administering hospitals, diagnostic centers and research centers.

Fortis Healthcare Ltd

Fortis Healthcare Ltd

Scorecard

Financial Statements

What is an income statement?

Income Statement

Lower than Industry Revenue Growth
A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Decreasing Market Share
Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Company Updates

Fortis Healthcare Ltd

Scorecard

Financial Statements

What is an income statement?

Income Statement

Lower than Industry Revenue GrowthA higher-than-industry revenue growth represents increased potential for the company to increase their market share

Decreasing Market ShareMarket share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Company Updates

Lower than Industry Revenue Growth
A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Decreasing Market Share
Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors